OncoCyte Co. (NASDAQ:OCX – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 1,070,000 shares, a decline of 24.6% from the May 31st total of 1,420,000 shares. Based on an average daily volume of 335,500 shares, the short-interest ratio is presently […]
OncoCyte Co. (NASDAQ:OCX – Free Report) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 1,070,000 shares, a decline of 24.6% from the May 31st total of 1,420,000 shares. Based on an average daily volume of 335,500 shares, the days-to-cover ratio is currently […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock […]
Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $1.40 to $0.45 and set a “buy” rating on the stock in […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Friday morning. The firm issued a sell rating on the stock. Separately, Needham & Company LLC decreased their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating for the company in a research […]